Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kai Pharmaceuticals has started enrollment in a Phase I clinical study of KAI-1678, a first-in-class, isozyme-selective inhibitor of the epsilon protein kinase C pathway.
Subscribe to our email newsletter
Kai’s randomized, double-blind, placebo-controlled, rising single-dose study will evaluate the safety, tolerability and pharmacokinetics of KAI-1678 in healthy males. The study will enroll five cohorts and is expected to complete this quarter. The study is being conducted in Australia.
KAI-1678 has been shown to be highly effective at reducing pain responses in a wide variety of preclinical pain models.
Gregory Bell, senior vice president of development and chief medical officer of Kai, said: “Epsilon PKC has been shown to have an important role in both inflammatory and neuropathic pain. Current therapies for the management of pain, such as opioids and nonsteroidal anti-inflammatory drugs, can be limited by side effects and inadequate efficacy. There is a need for novel therapeutics with unique mechanisms of action that provide effective pain relief with reduced side effects.”